Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
The effect of neonatal vitamin A supplementation on growth in the first year of life among low-birth-weight infants in Guinea-Bissau: Two by two factorial randomised controlled trial
BMC Pediatrics, Volume 13, No. 1, Article 87, Year 2013
Notification
URL copied to clipboard!
Description
Background: Vitamin A supplementation (VAS) may amplify the effect of vaccines. We therefore investigated if neonatal VAS given with and without Bacille Calmette-Guérin (BCG) vaccine to low-birth-weight (LBW) neonates had an effect on growth in the first year of life. We hypothesised that VAS would be particularly beneficial when provided with BCG.Methods: We conducted a randomised two-by-two factorial trial in Guinea-Bissau; 1,717 LBW neonates were randomly allocated to VAS or placebo at birth as well as early or the usual postponed BCG vaccination. Anthropometric measurements were obtained at 2, 6, and 12 months after inclusion.Results: Overall there was no effect of neonatal VAS on growth in the first year of life. By 2 months, VAS tended to have a beneficial effect on weight and head circumference when given with BCG but not when given without BCG (interaction: weight-for-age p = 0.07 and head circumference-for-age: p = 0.06). By 6 months, there was a beneficial effect of VAS on head circumference and weight among children who had not received DTP vaccine 2 months after inclusion (weight: 0.18 (0.00; 0.36) and head circumference 0.27 (0.06; 0.48)), but no beneficial effect among those who had received DTP.Conclusion: The results support other trials indicating that neonatal VAS does not have consistent effects on childhood growth and if anything the effects seem to be temporary. They also show that the effect may differ by vaccination status, being beneficial when given with BCG at birth and when DTP is delayed.Trial registration: http://www.ClinicalTrials.gov (NCT00168610) (nct00168610). © 2013 Biering-Sørensen et al.; licensee BioMed Central Ltd.
Available Materials
https://efashare.b-cdn.net/share/pmc/articles/PMC3680237/bin/1471-2431-13-87-S1.xls
https://efashare.b-cdn.net/share/pmc/articles/PMC3680237/bin/1471-2431-13-87-S2.xls
Authors & Co-Authors
Biering-Sørensen, Sofie
Denmark, Copenhagen
Statens Serum Institut
Ghana, Accra
Indepth Network
Fisker, Ane Bærent
Denmark, Copenhagen
Statens Serum Institut
Ghana, Accra
Indepth Network
Ravn, Henrik
Denmark, Copenhagen
Statens Serum Institut
Camala, Luis
Guinea-bissau
Hospital Nacional Simão Mendes
Monteiro, Ivan
Ghana, Accra
Indepth Network
Aaby, Peter
Ghana, Accra
Indepth Network
Benn, Christine Stabell
Denmark, Copenhagen
Statens Serum Institut
Statistics
Citations: 9
Authors: 7
Affiliations: 3
Identifiers
Doi:
10.1186/1471-2431-13-87
e-ISSN:
14712431
Research Areas
Maternal And Child Health
Study Design
Randomised Control Trial
Study Locations
Guinea
Guinea-Bissau